for investors

Scientific Presentations

Scientific Presentations

Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor
PDF
Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor
Anticonvulsive properties of soticlestat, a novel cholesterol 24-hydroxylase inhibitor
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
PDF
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
Pharmacokinetics, pharmacodynamics and safety assessment of multiple doses of soticlestat in healthy volunteers
Major Motor Drop Seizures for Endpoint Assessments in a Phase 3 Trial of Soticlestat in Individuals with Lennox–Gastaut Syndrome
PDF
Major Motor Drop Seizures for Endpoint Assessments in a Phase 3 Trial of Soticlestat in Individuals with Lennox–Gastaut Syndrome
Major Motor Drop Seizures for Endpoint Assessments in a Phase 3 Trial of Soticlestat in Individuals with Lennox–Gastaut Syndrome
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
PDF
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor, reduces seizures and premature death in Dravet syndrome mice
Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)
PDF
Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)
Discovery of Soticlestat, a Potent and Selective Inhibitor for Cholesterol 24-Hydroxylase (CH24H)
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
PDF
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies.
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
PDF
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
Long-Term Soticlestat Treatment in Patients with Developmental and/or Epileptic Encephalopathies in the ENDYMION Ongoing Open-Label Extension Study
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
PDF
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
Safety, tolerability, pharmacokinetics, pharmacodynamics, bioavailability and food effect of single doses of soticlestat in healthy subjects
Quantitative analysis of EEG signals in STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome
PDF
Quantitative analysis of EEG signals in STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome
Quantitative analysis of EEG signals in STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)
PDF
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)
Efficacy, Safety and Tolerability of Soticlestat (TAK-935/OV935) as Adjunctive Therapy in Pediatric Patients with Dravet Syndrome and Lennox-Gastaut Syndrome (ELEKTRA)
TAK-935 (OV935) Exerts Neuroprotective and Disease-Modifying Effects in a Murine Model of Epileptogenesis
PDF
TAK-935 (OV935) Exerts Neuroprotective and Disease-Modifying Effects in a Murine Model of Epileptogenesis
TAK-935 (OV935) Exerts Neuroprotective and Disease-Modifying Effects in a Murine Model of Epileptogenesis
Caregiver insight on the core domains in Angelman syndrome
PDF
Caregiver insight on the core domains in Angelman syndrome
Caregiver insight on the core domains in Angelman syndrome
The Phase 2a ROCKET trial investigating gaboxadol (OV101) in adolescents and young adults with fragile X syndrome
PDF
The Phase 2a ROCKET trial investigating gaboxadol (OV101) in adolescents and young adults with fragile X syndrome
The Phase 2a ROCKET trial investigating gaboxadol (OV101) in adolescents and young adults with fragile X syndrome
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
PDF
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome: seizure and EEG outcomes
PDF
STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome: seizure and EEG outcomes
STARS, a Phase 2 safety, tolerability, and exploratory efficacy study of gaboxadol in adolescents and adults with Angelman syndrome: seizure and EEG outcomes
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
PDF
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Soticlestat, a novel cholesterol 24-hydroxylase inhibitor shows a therapeutic potential for neural hyperexcitation in mice
Concomitant medication use in adolescent and adult individuals with Angelman syndrome: baseline results from the phase 2 STARS study
PDF
Concomitant medication use in adolescent and adult individuals with Angelman syndrome: baseline results from the phase 2 STARS study
Concomitant medication use in adolescent and adult individuals with Angelman syndrome: baseline results from the phase 2 STARS study
Initial data from the ongoing ENDYMION open-label extension trial of soticlestat (TAK-935/OV935) in participants with developmental and/or epileptic encephalopathies (DEE)
PDF
Initial data from the ongoing ENDYMION open-label extension trial of soticlestat (TAK-935/OV935) in participants with developmental and/or epileptic encephalopathies (DEE)
Initial data from the ongoing ENDYMION open-label extension trial of soticlestat (TAK-935/OV935) in participants with developmental and/or epileptic encephalopathies (DEE)
A phase 1b/2a study of soticlestat (TAK-935 /OV935) as adjunctive therapy in patients with developmental and epileptic encephalopathies
PDF
A phase 1b/2a study of soticlestat (TAK-935 /OV935) as adjunctive therapy in patients with developmental and epileptic encephalopathies
A phase 1b/2a study of soticlestat (TAK-935 /OV935) as adjunctive therapy in patients with developmental and epileptic encephalopathies
The Phase 2a ROCKET trial investigating OV101 (gaboxadol) in adolescents and young adults with Fragile X syndrome
PDF
The Phase 2a ROCKET trial investigating OV101 (gaboxadol) in adolescents and young adults with Fragile X syndrome
The Phase 2a ROCKET trial investigating OV101 (gaboxadol) in adolescents and young adults with Fragile X syndrome
Quality of life in adolescent and adult individuals with Angelman syndrome: baseline results from the Phase 2 STARS study
PDF
Quality of life in adolescent and adult individuals with Angelman syndrome: baseline results from the Phase 2 STARS study
Quality of life in adolescent and adult individuals with Angelman syndrome: baseline results from the Phase 2 STARS study
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
PDF
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions
The pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome: study overview and rationale
PDF
The pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome: study overview and rationale
The pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome: study overview and rationale
Caregiver insight on the core domains in Angelman syndrome
PDF
Caregiver insight on the core domains in Angelman syndrome
Caregiver insight on the core domains in Angelman syndrome
Physiologically based pharmacokinetic (PBPK) modeling for OV101 (gaboxadol) exposure in children with Angelman syndrome
PDF
Physiologically based pharmacokinetic (PBPK) modeling for OV101 (gaboxadol) exposure in children with Angelman syndrome
Physiologically based pharmacokinetic (PBPK) modeling for OV101 (gaboxadol) exposure in children with Angelman syndrome
Differential pharmacodynamics of once vs. twice daily OV101 (gaboxadol) administration: Evidence of pharmacodynamic tolerance with twice daily gaboxadol dosing in individuals with Angelman syndrome
PDF
Differential pharmacodynamics of once vs. twice daily OV101 (gaboxadol) administration: Evidence of pharmacodynamic tolerance with twice daily gaboxadol dosing in individuals with Angelman syndrome
Differential pharmacodynamics of once vs. twice daily OV101 (gaboxadol) administration: Evidence of pharmacodynamic tolerance with twice daily gaboxadol dosing in individuals with Angelman syndrome
Cognitive Assessment After Multiple Ascending Doses of TAK-935 (OV935) in Healthy Subjects
PDF
Cognitive Assessment After Multiple Ascending Doses of TAK-935 (OV935) in Healthy Subjects
Cognitive Assessment After Multiple Ascending Doses of TAK-935 (OV935) in Healthy Subjects
Evaluation of TAK-935 (OV935) on seizures and survival in Scn1a+/-Dravet Mice
PDF
Evaluation of TAK-935 (OV935) on seizures and survival in Scn1a+/-Dravet Mice
Evaluation of TAK-935 (OV935) on seizures and survival in Scn1a+/-Dravet Mice
Inhibition of Cholesterol 24-Hydroxylase Improves the Survival of a Mouse Model of Epileptic Phenotype and Modulates Extracellular Levels of Glutamate
PDF
Inhibition of Cholesterol 24-Hydroxylase Improves the Survival of a Mouse Model of Epileptic Phenotype and Modulates Extracellular Levels of Glutamate
Inhibition of Cholesterol 24-Hydroxylase Improves the Survival of a Mouse Model of Epileptic Phenotype and Modulates Extracellular Levels of Glutamate
Evaluation of Pharmacodynamic Effects of Cholesterol 24-Hydroxylase Inhibitor TAK-935 and Its Target Engagement in Animals
PDF
Evaluation of Pharmacodynamic Effects of Cholesterol 24-Hydroxylase Inhibitor TAK-935 and Its Target Engagement in Animals
Evaluation of Pharmacodynamic Effects of Cholesterol 24-Hydroxylase Inhibitor TAK-935 and Its Target Engagement in Animals
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subject
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subject
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of TAK-935 in Healthy Subject
Inhibition of Cholesterol 24-Hydroxylase Is a Novel Pharmacological Strategy for Epilepsy Treatment
PDF
Inhibition of Cholesterol 24-Hydroxylase Is a Novel Pharmacological Strategy for Epilepsy Treatment
Inhibition of Cholesterol 24-Hydroxylase Is a Novel Pharmacological Strategy for Epilepsy Treatment
STARS: Results from a Safety and Efficacy Study of OV101 (Gaboxadol) in Adults and Adolescents with Angelman Syndrome
PDF
STARS: Results from a Safety and Efficacy Study of OV101 (Gaboxadol) in Adults and Adolescents with Angelman Syndrome
STARS: Results from a Safety and Efficacy Study of OV101 (Gaboxadol) in Adults and Adolescents with Angelman Syndrome
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of TAK-935 in Healthy Subjects
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of TAK-935 in Healthy Subjects
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of TAK-935 in Healthy Subjects
Clinical Trial Simulations Using a Pharmacokinetic/Enzyme-Occupancy/Pharmacodynamic Model of TAK-935, a Cholesterol 24S-Hydroxylase Inhibitor
PDF
Clinical Trial Simulations Using a Pharmacokinetic/Enzyme-Occupancy/Pharmacodynamic Model of TAK-935, a Cholesterol 24S-Hydroxylase Inhibitor
Clinical Trial Simulations Using a Pharmacokinetic/Enzyme-Occupancy/Pharmacodynamic Model of TAK-935, a Cholesterol 24S-Hydroxylase Inhibitor

Cautionary Statement and Acknowledgment

By proceeding further, you acknowledge and agree that your access to information contained in the "Scientific Presentations" section of the Ovid Therapeutics website:

  • Is provided for informational purposes for use by the investor community only; and
  • May include information about investigational compounds that have not been approved by the applicable regulatory authorities as safe and effective.

In addition, the scientific or medical presentations included in the "Scientific Presentations" section of the Ovid Therapeutics website may contain forward-looking statements, within the meaning of the Private Securities Reform Act of 1995. Forward-looking statements may be accompanied by such words as "anticipate," "believe," "could," "estimate," "expect," "forecast," "intend," "may," "plan," "potential," "possible," "will" and other words and terms of similar meaning. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including those risks and uncertainties that are described in the Risk Factors section of Ovid Therapeutics most recent annual or quarterly report and in other reports Ovid Therapeutics has filed with the Securities and Exchange Commission (SEC) available at the SEC’s Internet (www.sec.gov). You should not place undue reliance on these statements or the scientific data presented. Forward-looking statements speak only as of the date of each presentation. Except as required by law, Ovid Therapeutics does not have any intention or undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future developments, changes in assumptions or otherwise.

Decline